Sort
10,766 grants matching “checkpoint inhibitor”
Mechanistic Inflammatory Pathways in Graft Versus Host Disease
$695,482William R. Drobyski · Medical College Of Wisconsin · R01 · FY2020 · HL
Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation
$695,333Katerina Abigail Politi · Yale University · R01 · FY2020 · CA
Targeting T cell dysfunction in glioblastoma: A proof-of-concept Phase 0/I trial of anti-TIGIT antibody AB154 in combination with anti-PD1 antibody AB122
$695,125Antonio M Omuro · Yale University · R01 · FY2022 · CA
NONINVASIVE DIAGNOSIS OF IMMUNE CHECKPOINT INHIBITOR-ASSOCIATED MYOCARDITIS
$695,048Dana-Farber Cancer Institute, Inc. · · FY2022 · Defense Health Agency
Project 1: Investigation of immune and stromal factors that promote prostate adenocarcinoma progression and castration response
$695,029Charles L Sawyers · Columbia University Health Sciences · P01 · FY2022 · CA
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy
$694,766Youngho Seo · University Of California, San Francisco · R01 · FY2023 · HL
Immune Response to RBC Antigens
$694,350Krystalyn E Hudson · Columbia University Health Sciences · R01 · FY2024 · HL
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity
$694,227Sharon S Evans · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer
$693,903Emese Zsiros · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA
Targeting the tumor microenvironment with engineered CD4+ T cells
$693,880Joshua R Veatch · Fred Hutchinson Cancer Center · R37 · FY2024 · CA
Targeting the tumor microenvironment with engineered CD4+ T cells
$693,880Joshua R Veatch · Fred Hutchinson Cancer Center · R37 · FY2025 · CA
Harnessing mutant IDH1 as a therapeutic target in liver cancer and other solid malignancies
$693,781Nabeel Bardeesy · Massachusetts General Hospital · R01 · FY2025 · CA
Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer
$693,171Scott McNear Thacher · Orphagen Pharmaceuticals · R44 · FY2022 · CA
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors
$692,707Sumit K Chanda · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2019 · CA
Optimizing immunoradiotherapy for HNSCC
$692,235Joseph A Califano · University Of California, San Diego · R01 · FY2023 · CA
Molecular Imaging and Theranostics of Cancer
$691,623Zaver M Bhujwalla · Johns Hopkins University · R35 · FY2017 · CA
Re-engineering differential regulation of ferroptosis in melanoma microenvironment
$690,908Yuri Bunimovich · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Combinatorial application of nanoscale technologies to target a novel mechanism of immune evasion by cancer cells
$690,825Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2025 · CA
Combinatorial application of nanoscale technologies to target a novel mechanism of immune evasion by cancer cells
$690,825Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2024 · CA
The Transmembrane Protein Disulfide Isomerase TMX1 Negatively Regulates Thrombosis
$690,273David W Essex · Temple Univ Of The Commonwealth · R01 · FY2025 · HL
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
$690,258Diane M Simeone · New York University School Of Medicine · R01 · FY2021 · CA
Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitors
$689,934Toni Choueiri · Dana-Farber Cancer Inst · R01 · FY2024 · CA
The Thromboxane-Prostanoid Receptor in Radiation-Induced Pulmonary Fibrosis
$689,596James D West · Vanderbilt University Medical Center · R01 · FY2024 · CA
Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancer
$689,468Ping Chi · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
Synthetic lethal targeting of EBV-positive diffuse large B cell lymphomas in persons living with HIV
$689,270Sumita Bhaduri-McIntosh · University Of Florida · U01 · FY2022 · CA